Efforts are being made to optimize early-phase clinical trials, with a focus on minimizing risk and improving decision-making. The use of artificial intelligence and innovation in clinical trials is being explored, and regulatory guidance is being developed, including new guidance from the FDA on clinical trial dosage for certain oncology treatments. The optimization efforts appear to be relevant to various types of cancer, including breast cancer and head and neck cancer, as well as other therapeutic areas.